Pancreatic Cancer Research

ResearcherQingdao UniversityActive in the last 2 years

Ruining Gong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5016-8085; OpenAlex author ID A5019146270, A5159299448. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: 1 paper · 2023: none · 2024: 3 papers · 2025: 4 papers · 2026: 5 papers

Papers 15

  1. EGFR-Targeting IgG1 Antibody Enhances NK Cell-Mediated Tumor Killing in KRAS-Mutant Pancreatic Cancer. Co-author DOI 10.1002/mco2.70860↗
  2. Identification of mitochondrial oxidative stress-related genes for estimating prognosis, immune infiltration landscape and drug candidates in pancreatic adenoc… Co-author DOI 10.1007/s12672-026-04948-8↗
  3. Cancer cell-specific FOXP3 licenses MMP19-dependent matrix remodeling and metastatic dissemination in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-026-04025-y↗
  4. Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory facto… Co-author DOI 10.1038/s41392-025-02562-8↗
  5. NUP93 facilitates the nuclear import of SOX2 to activate G3BP1 transcription and impairs gemcitabine response in pancreatic cancer. Co-author DOI 10.1038/s41419-026-08586-4↗
  6. hnRNPLL regulates MYOF alternative splicing and correlates with early metastasis in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.canlet.2024.217436↗
  7. Design of nano-delivery systems for pancreatic cancer immunotherapy. Co-author DOI 10.1016/j.canlet.2025.218098↗
  8. HCST Expression Distinguishes Immune-hot and Immune-cold Subtypes in Pancreatic Ductal Adenocarcinoma Co-author DOI 10.2174/1566523223666230720101531↗
  9. Targeting myeloid cells in pancreatic ductal adenocarcinoma: from primary tumors to liver metastasis. Co-author DOI 10.3389/fimmu.2025.1555036↗
  10. Expression landscape of cancer-FOXP3 and its prognostic value in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.216838↗
  11. Hepatic Macrophage Migration Inhibitory Factor Promotes Pancreatic Cancer Liver Metastasis in NAFLD Co-author DOI 10.1101/2024.06.02.595997↗
  12. hnRNPAB Promotes Pancreatic Ductal Adenocarcinoma Extravasation and Liver Metastasis by Stabilizing MYC mRNA. Co-author DOI 10.1158/1541-7786.mcr-24-0110↗
  13. Injectable Immunotherapeutic Hydrogel Containing RNA-Loaded Lipid Nanoparticles Reshapes Tumor Microenvironment for Pancreatic Cancer Therapy. Co-author DOI 10.1021/acs.nanolett.2c01994↗
  14. Targeting chemokines/chemokine receptors: a promising strategy for enhancing the immunotherapy of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41392-020-00267-8↗
  15. Non-coding RNAs in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2020.00309↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. He Ren · 11 shared papers, 2020–2026 · strength 2.49
  2. Ke Lei · 5 shared papers, 2024–2026 · strength 1.18
  3. Qian Yu · 5 shared papers, 2024–2026 · strength 1.09
  4. Xianghan Chen · 4 shared papers, 2024–2025 · strength 0.90
  5. Chao Gao · 3 shared papers, 2022–2026 · strength 0.60
  6. Jigang Wang · 3 shared papers, 2024–2025 · strength 0.60
  7. Junjin Wang · 2 shared papers, 2026 · strength 0.59
  8. Ashok Kumar Saluja · 3 shared papers, 2024–2026 · strength 0.59
  9. Zhan Yang · 2 shared papers, 2025–2026 · strength 0.54
  10. Huan Zhang · 2 shared papers, 2025–2026 · strength 0.49
  11. Ruiguang Ma · 1 shared paper, 2026 · strength 0.43
  12. Yueping Jiang · 1 shared paper, 2026 · strength 0.43
  13. Xiuchao Wang · 1 shared paper, 2026 · strength 0.32
  14. Qian Yu · 1 shared paper, 2025 · strength 0.30
  15. Zimin Liu · 1 shared paper, 2025 · strength 0.30
  16. David Kuang-Fu Chang · 1 shared paper, 2025 · strength 0.30
  17. Hao Sun · 1 shared paper, 2026 · strength 0.30
  18. Ruoxi Xiao · 1 shared paper, 2026 · strength 0.28
  19. Boyi Ma · 1 shared paper, 2025 · strength 0.27
  20. Yueping Jiang · 1 shared paper, 2020 · strength 0.24
  21. Shunli Fu · 1 shared paper, 2025 · strength 0.24
  22. Shanglong Liu · 1 shared paper, 2026 · strength 0.19
  23. Xiaoya Shi · 1 shared paper, 2026 · strength 0.19
  24. Qinghui Niu · 1 shared paper, 2026 · strength 0.19
  25. Jieer Ying · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.